Edwards Lifesciences Corp

Natural and catastrophic events · Ecosystem and biodiversity collapse

We are subject to risks arising from concerns and/or regulatory actions relating to animal-borne illnesses, including "mad cow disease." Certain of our products, including pericardial tissue valves, are manufactured using bovine tissue. Concerns relating to the potential transmission of animal-borne illnesses, including BSE, commonly known as "mad cow disease," from cows to humans may result in reduced acceptance of products containing bovine materials.

Natural and catastrophic events · Climate change and environmental impact

Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our future operations from natural disasters and extreme weather conditions, such as hurricanes, tornadoes, seismic events, wildfires, or flooding. Such extreme weather conditions could pose physical risks to our facilities and disrupt operation of our supply chain and may impact operational costs.

Natural and catastrophic events · Natural disasters and extreme weather

Disruptions can also occur if our manufacturing and warehousing facilities are damaged by earthquakes, hurricanes, volcanoes, fires, and other natural disasters or catastrophic circumstances. As we expand into new markets and scale new products for commercial production, we may face unanticipated delays or surges in demand which could strain our production capacity.

Data and privacy · Data protection and privacy laws

Failure to comply with data privacy and security laws could have a material adverse effect on our business. We are required to comply with increasingly complex and changing legal and regulatory requirements that govern the collection, use, storage, security, transfer, disclosure, and other processing of personal data in the United States and in other countries, which may include, but are not limited to, the Health Insurance Portability and Accountability Act ("HIPPA"), the General Data Protection Regulation ("GDPR"), and the California Privacy Rights Act ("CRPA") and the California Consumer Privacy Act.

Industry regulation · Safety and environmental regulations

Our operations are subject to environmental, health, and safety laws, and regulations concerning, among other things, the generation, handling, transportation, and disposal of hazardous substances or wastes, the cleanup of hazardous substance releases, and emissions or discharges into the air or water. We have incurred and may incur in the future expenditures in connection with environmental, health, and safety laws and regulations.

Legal and litigation · Product liability and warranty claims

Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical technologies. Many of the devices we manufacture and sell are designed to be implanted in the human body for long periods of time. Component failures, manufacturing and assembly flaws, design defects, software defects, medical procedure errors, or inadequate disclosure of product-related risks or information could result in an unsafe condition for, injury to, or death of patients.

Industry regulation · Regulatory compliance and changes

Health care legislation and other regulations may adversely impact access to and demand for our products. We are subject to various federal and foreign laws that govern our domestic and international business practices. For example, in the United States, continued implementation of the Affordable Care Act and the 21st Century Cures Act, or any future legislation, including deficit reduction legislation, could impact medical procedure volumes, reimbursement for our products, and demand for our products.

Cybersecurity and data protection · Data breaches and cyber attacks

Our information technology infrastructure and products are vulnerable to cybersecurity attacks. Cybersecurity attacks can include, but are not limited to, computer viruses, denial-of-service attacks, phishing attacks, ransomware attacks, and other introduction of malware to computers and networks; social engineering or other unauthorized access through the use of compromised credentials; exploitation of design flaws, bugs, or security vulnerabilities.

Digital transformation and innovation · Artificial intelligence and automation

Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain. The rapid advancement of these technologies entails risks, including potential deficiencies in AI-generated information and increased regulatory, cybersecurity, privacy, intellectual property and data-related risks.

Cybersecurity and data protection · Third party data security and vendors

We rely upon technology suppliers, including cloud‑based data management applications hosted by third‑party service providers, whose cybersecurity and information technology systems are subject to similar risks. Significant disruption in either our or our service providers' or suppliers' information technology or the security of our products could impede our operations or result in decreased sales.

Innovation and product development · Product development and randd investment risks

Our continued growth and success depend on our ability to innovate and develop new and differentiated products in a timely manner and effectively market these products. Without timely innovation and development, our products could be rendered obsolete or less competitive because of the introduction of a competitor's newer technologies or changing customer preferences.

Market position and competition · Industry consolidation and market concentration

Continued consolidation in the health care industry could have an adverse effect on our sales and results of operations. The health care industry has been consolidating, and organizations such as GPOs, independent delivery networks, and large single accounts, such as the United States Veterans Administration, continue to consolidate purchasing decisions for many of our health care provider customers. The purchasing power of these larger customers has increased, and may continue to increase, causing downward pressure on product pricing.

Strategic execution · Merger acquisition and divestiture risks

Failure to successfully integrate acquired businesses, technologies or strategic alliances, or challenges related to the execution of acquisitions or divestitures, as well as liabilities or claims relating to such acquired businesses or divestitures, could adversely affect our business and results of operations. The integration of acquired businesses and technologies may be costly and may divert significant amounts of resources, including management and employee time and attention.

Customer and revenue · Customer concentration and key customer dependence

The success of many of our products depends upon certain key physicians, research institutions, and hospital systems. If new laws, regulations, or other developments limit our ability to appropriately engage these professionals or with the research institutions of which they are a part or to continue to receive their advice and input or we are otherwise unsuccessful in maintaining strong working relationships with these physicians or their research institutions, the development, marketing, and successful use of our products could suffer.

Customer and revenue · Reimbursement and pricing pressure healthcare or insurance

If government or other third-party payors decline to reimburse our customers for our products or impose other cost containment measures to reduce reimbursement levels, our ability to profitably sell our products will be harmed. Government and other third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services.

Core operations · Quality control and product defects

The manufacture and sterilization of many of our products are highly complex due in part to rigorous regulatory requirements. Quality is extremely important for many reasons, including due to the serious and costly consequences of a product failure. Problems can arise for a number of reasons, including disruption of facility utilities, equipment malfunction, failure to follow protocols and procedures, raw material problems, software problems, cybersecurity incidents, or human error.

Human capital and workforce · Key personnel dependence and succession

Our continued success depends, in large part, on our ability to hire and retain qualified people and execute on our talent management and succession plans, and if we are unable to do so, our business and operations may be impaired or disrupted.

Core operations · Capacity utilization and efficiency

As we expand into new markets and scale new products for commercial production, we may face unanticipated delays or surges in demand which could strain our production capacity and lead to other types of disruption.

Supply chain and procurement · Raw material availability and cost volatility

Any significant increases in the cost of raw materials, whether due to inflationary pressure, supply constraints, the imposition of tariffs, regulatory changes, or otherwise, could adversely impact our operating results.

International and currency · International operations and emerging markets

Our international operations subject us to certain business risks including trade protection measures, quotas, embargoes, import or export requirements, and duties, tariffs, or surcharges; cultural or other local factors affecting financial terms with customers; global regulations including those related to health care, labor and environmental, social and governance; military conflict, political unrest, or wars; scrutiny from governmental bodies regarding the pricing of our products.